Stormy Chamberlain is associate professor of genetics and genome sciences and associate director of the Graduate Program in Genetics and Developmental Biology at the University of Connecticut School of Medicine.
![](https://www.thetransmitter.org/wp-content/uploads/2018/04/chamberlain170.jpg)
Stormy Chamberlain
Associate professor
University of Connecticut
From this contributor
Angelman syndrome’s silent gene points way forward for autism therapies
Advances in research and help from families have brought scientists to the brink of an effective therapy for Angelman syndrome.
![](https://www.thetransmitter.org/wp-content/uploads/2019/10/20190921-Angelman1120.jpg)
Angelman syndrome’s silent gene points way forward for autism therapies
For accurate results in autism, genetic databases need diversity
We must diversify databases of reference DNA to improve our ability to interpret the consequences of genetic variation.
![](https://www.thetransmitter.org/wp-content/uploads/2018/04/20180410-Chamberlain1120y.jpg)
For accurate results in autism, genetic databases need diversity
Explore more from The Transmitter
Cell population in brainstem coordinates cough, new study shows
The work also adds to a growing body of evidence showing that mice, and their genetic toolbox, can be used to study cough.
![](https://www.thetransmitter.org/wp-content/uploads/2024/09/1200_coughingmice-1024x720.webp)
Cell population in brainstem coordinates cough, new study shows
The work also adds to a growing body of evidence showing that mice, and their genetic toolbox, can be used to study cough.
In updated U.S. autism bill, Congress calls for funding boost, expanded scope
The current Autism CARES Act sunsets in late September.
![Capitol building](https://www.thetransmitter.org/wp-content/uploads/2024/09/capitolhill-1200-1024x692.webp)
In updated U.S. autism bill, Congress calls for funding boost, expanded scope
The current Autism CARES Act sunsets in late September.
Ketamine targets lateral habenula, setting off cascade of antidepressant effects
The drug’s affinity for overactive cells in the “anti-reward” region may help explain its rapid and long-lasting results.
![Illustration of ketamine blocking open ion channels in active NMDA receptors, quieting the cells and disrupting downstream signaling involved in depression.](https://www.thetransmitter.org/wp-content/uploads/2024/09/1200-ketamine-receptor-transmitter-neuroscience-1024x683.webp)
Ketamine targets lateral habenula, setting off cascade of antidepressant effects
The drug’s affinity for overactive cells in the “anti-reward” region may help explain its rapid and long-lasting results.